Faculty profile

Fabrizio Giuliani

ResearcherMedicine/NeurologyUniversity of Alberta

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Alberta directory, so their courses may be missing. Find their university profile.

Fabrizio Giuliani

Researcher

Medicine/Neurology

Health Sciences

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
12 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Interferon Microglia Multiple Sclerosis Remyelination

Latest papers

Siglec-G on B cells restrains the germinal center response by controlling T cell help during positive selection.
bioRxiv : the preprint server for biology · 2026
Investigations of remibrutinib in models pertinent to multiple sclerosis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
Generation of oligodendrocyte precursor-like cells from mouse embryonic fibroblasts using miR-7a mimics.
Iranian journal of basic medical sciences · 2026 · senior author

All 42 publications

Latest funding

Interferon responsive microglia regulate remyelination
CIHR · 2025 · Principal investigator
$1,361,700
Aging impairs microglial phagocytosis and stalls remyelination
CIHR · 2023 · Co-investigator
$1,350,225
Biodegradable acidic nanoparticles attenuate beta-amyloid aggregation/toxicity: potential implication in the treatment of Alzheimer's disease pathology
CIHR · 2021 · Co-investigator
$730,576

All 5 grants and awards

42 publications.

Siglec-G on B cells restrains the germinal center response by controlling T cell help during positive selection.

Enterina JR, Lin SY, Luna-Dulcey L, Sarkar S, Schmidt EN, Jame-Chenarboo Z, Chisholm K, Haq AU, Luo S, Laurent CDS, Ataei T, Giuliani F, Julien O, Macauley MS

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.05.06.723371 PMID: 42182281

Investigations of remibrutinib in models pertinent to multiple sclerosis.

Jain RW, Rayatpour A, Hagen K, Morch MT, Randhawa G, Mobarakabadi M, Zhang X, Li C, Nakhaei-Nejad M, Giuliani F, Cenni B, Xue M, Yong VW

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

DOI: 10.1016/j.neurot.2026.e00923 PMID: 42134274

Generation of oligodendrocyte precursor-like cells from mouse embryonic fibroblasts using miR-7a mimics.

Ghasemi-Kasman M, Nakhaei-Nejad M, Rabiei F, Giuliani F

Iranian journal of basic medical sciences2026Senior author

DOI: 10.22038/ijbms.2026.96127.20729 PMID: 42788001

Serum neurofilament light chain as a biomarker in multiple sclerosis: A cross-sectional observation in real-world clinical practice.

Sahoo S, Harper C, Tsui AKY, Nakhaei-Nejad M, Fong T, Blevins G, Giuliani F

Multiple sclerosis and related disorders2025Senior author

DOI: 10.1016/j.msard.2025.106637 PMID: 40840335

Cervical Spinal Cord Magnetization Transfer Ratio and Its Relationship With Clinical Outcomes in Multiple Sclerosis.

Lee LE, Cohen-Adad J, Vavasour IM, Guenette M, Sawicka K, Rashidi-Ranjbar N, Churchill N, Chopra A, Adelia A, Benveniste PL, Traboulsee A, Arbour N, Giuliani F, Lynd LD, Patten SB, Prat A, Schabas A, Smyth P, Tam R, Zhang Y, Graham SJ, Hodaie M, Feinstein A, Kolind S, Schweizer TA, Oh J, CanProCo Study Group

Annals of clinical and translational neurology2025

DOI: 10.1002/acn3.70113 PMID: 40583289

Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.

Mao-Draayer Y, Bar-Or A, Balashov K, Foley J, Smoot K, Longbrake EE, Robertson D, Mendoza JP, Lewin JB, Everage N, Božin I, Lyons J, Mokliatchouk O, Bame E, Giuliani F

Advances in therapy2025Senior author

DOI: 10.1007/s12325-024-03047-w PMID: 39570545

The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics.

Oh J, Arbour N, Giuliani F, Guenette M, Kolind S, Lynd L, Marrie RA, Metz LM, Prat A, Schabas A, Smyth P, Tam R, Traboulsee A, Yong VW, Patten SB

Therapeutic advances in neurological disorders2024

DOI: 10.1177/17562864241273045 PMID: 39282637

Fractalkine enhances oligodendrocyte regeneration and remyelination in a demyelination mouse model.

de Almeida MMA, Watson AES, Bibi S, Dittmann NL, Goodkey K, Sharafodinzadeh P, Galleguillos D, Nakhaei-Nejad M, Kosaraju J, Steinberg N, Wang BS, Footz T, Giuliani F, Wang J, Sipione S, Edgar JM, Voronova A

Stem cell reports2023

DOI: 10.1016/j.stemcr.2022.12.001 PMID: 36608690

Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology.

Anand B, Wu Q, Nakhaei-Nejad M, Karthivashan G, Dorosh L, Amidian S, Dahal A, Li X, Stepanova M, Wille H, Giuliani F, Kar S

Bioactive materials2022

DOI: 10.1016/j.bioactmat.2022.05.030 PMID: 36330076

Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: Potential significance in Alzheimer's disease pathology.

Wu Q, Karthivashan G, Nakhaei-Nejad M, Anand BG, Giuliani F, Kar S

International journal of biological macromolecules2022

DOI: 10.1016/j.ijbiomac.2022.08.148 PMID: 36030976

Something wrong or missing on this profile? Suggest a correction

Fabrizio Giuliani

Research

Latest papers

Latest funding

Siglec-G on B cells restrains the germinal center response by controlling T cell help during positive selection.

Investigations of remibrutinib in models pertinent to multiple sclerosis.

Generation of oligodendrocyte precursor-like cells from mouse embryonic fibroblasts using miR-7a mimics.

Serum neurofilament light chain as a biomarker in multiple sclerosis: A cross-sectional observation in real-world clinical practice.

Cervical Spinal Cord Magnetization Transfer Ratio and Its Relationship With Clinical Outcomes in Multiple Sclerosis.

Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase&#xa0;4 and PROCLAIM Phase&#xa0;3 Studies with a Focus on Older Patients.

The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics.

Fractalkine enhances oligodendrocyte regeneration and remyelination in a demyelination mouse model.

Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology.

Native PLGA nanoparticles regulate APP metabolism and protect neurons against &#x3b2;-amyloid toxicity: Potential significance in Alzheimer's disease pathology.

Interferon responsive microglia regulate remyelination

Aging impairs microglial phagocytosis and stalls remyelination

Biodegradable acidic nanoparticles attenuate beta-amyloid aggregation/toxicity: potential implication in the treatment of Alzheimer's disease pathology

Stress-Dependent Regulation of Mitochondria-ER Membrane Dynamics by Rab32 in Neuroinflammation

Quantitative MRI for Multiple Sclerosis

Frequent collaborators

Jiwon Oh

Anthony Traboulsee

Christopher Power

Penelope Smyth

Thomas Simmen

Simonetta Sipione

Nathalie Arbour

Shannon Kolind

Alexandre Prat

Christian Beaulieu

Larry Lynd

Satyabrata Kar

Santanu Chakraborty

Catherine Larochelle

Xavier Montalban

Nicolas Touret

Yunyan Zhang

Pierre Duquette

Anna Taylor

Nathan Churchill

Christopher Power

Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.

Native PLGA nanoparticles regulate APP metabolism and protect neurons against β-amyloid toxicity: Potential significance in Alzheimer's disease pathology.